Biopolymer-based microneedles for transdermal pain relief
A FucoPol-based microneedle patch for effective transdermal delivery of pain-relieving agents like capsaicin and lidocaine. This dissolvable and biocompatible system enhances local delivery, minimizes side effects, and is suitable for over-the-counter use.
Overview
The biopolymer-based microneedle array technology utilizes FucoPol, a natural and biocompatible polysaccharide, to create dissolvable microneedle patches. These patches are designed for the transdermal delivery of pain-relieving agents, such as capsaicin and lidocaine, targeting neuropathic pain. By bypassing the skin's stratum corneum, this technology enhances local delivery, reducing systemic exposure and side effects. The FucoPol microneedles are safe, painless, and dissolve after use, avoiding sharp waste and ensuring consumer safety. The platform's versatility allows it to accommodate various pain-relief agents, making it ideal for convenient, over-the-counter applications.
Technical specifications
- Material: FucoPol, a biocompatible, bioactive bacterial polysaccharide
- Delivery Mechanism: Dissolving microneedles that bypass the skin barrier
- Active Ingredients: Compatible with capsaicin, lidocaine, and other neuropathic pain treatments
- Validation: Successfully tested with diclofenac sodium, demonstrating effective dissolution and in vitro release
- Adaptability: Suitable for various bioactive agents, with potential encapsulation strategies for poorly soluble compounds
Technology readiness level
Currently at TRL 4, this technology has been validated in vitro with diclofenac sodium. Future plans include incorporating other neuropathic pain agents and advancing to TRL 5-6 through further in vitro and ex vivo testing, optimizing formulation and microneedle design for improved delivery.
About Universidade NOVA de Lisboa
NOVA University Lisbon is a comprehensive public research institution spanning multiple campuses across the Lisbon metro area, combining selective excellence with an applied, collaborative ethos. Industry engages through co‑located laboratories at FCT NOVA and a science and technology park adjacent to the Caparica campus, alongside structured corporate partnership programs. Clinical translation is enabled by NOVA Medical School’s integration with Lisbon’s hospital network and clinical academic consortia, providing access to patient populations and real‑world settings. Research is supported by competitive European and Portuguese national funding, including Horizon Europe and the Foundation for Science and Technology, complemented by industry‑sponsored work. University‑wide innovation offices and school‑level TTOs provide IP, licensing, and startup support as a clear entry point for corporate R&D.
Inquire about this partnering listing
Industry applications
delivered to your inbox.